Myocardial Proteome in Human Heart Failure With Preserved Ejection Fraction

被引:0
作者
Jani, Vivek P. [1 ]
Yoo, Edwin J. [1 ]
Binek, Aleksandra [2 ]
Guo, Alina [1 ]
Kim, Julie S. [3 ]
Aguilan, Jennifer [4 ]
Keykhaei, Mohammad [1 ]
Jenkin, Sydney R. [1 ]
Sidoli, Simone [3 ]
Sharma, Kavita [1 ]
Van Eyk, Jennifer E. [2 ]
Kass, David A. [1 ,5 ,6 ]
Hahn, Virginia S. [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD USA
[2] Cedars Sinai Med Ctr, Adv Clin BioSyst Res Inst, Smidt Heart Inst, Los Angeles, CA USA
[3] Albert Einstein Coll Med, Dept Biochem, Bronx, NY USA
[4] Albert Einstein Coll Med, Dept Pathol, Bronx, NY USA
[5] Johns Hopkins Univ, Dept Pharmacol & Mol Sci, Baltimore, MD USA
[6] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD USA
来源
JOURNAL OF THE AMERICAN HEART ASSOCIATION | 2025年 / 14卷 / 06期
关键词
fatty acids; heart failure; metabolism; myocardium; obesity; oxidative phosphorylation; proteomics; QUANTIFICATION;
D O I
10.1161/JAHA.124.038945
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Heart failure with preserved ejection fraction (HFpEF) constitutes more than half of all HF but has few effective therapies. Recent human myocardial transcriptomics and metabolomics have identified major differences between HFpEF and controls. How this translates at the protein level is unknown.Methods and Results Myocardial tissue from patients with HFpEF and nonfailing donor controls was analyzed by data-dependent acquisition (n=10 HFpEF, n=10 controls) and data-independent acquisition (n=44 HFpEF, n=5 controls) mass spectrometry-based proteomics. Differential protein expression analysis, pathway overrepresentation, weighted coexpression network analysis, and machine learning were integrated with clinical characteristics and previously reported transcriptomics. Principal component analysis (data-dependent acquisition-mass spectrometry) found HFpEF separated into 2 subgroups: one similar to controls and the other disparate. Downregulated proteins in HFpEF versus controls were enriched in mitochondrial transport/organization, translation, and metabolism including oxidative phosphorylation. Proteins upregulated in HFpEF were related to immune activation, reactive oxygen species, and inflammatory response. Ingenuity pathway analysis predicted downregulation of protein translation, mitochondrial function, and glucose and fat metabolism in HFpEF. Expression of oxidative phosphorylation and metabolism genes (higher) versus proteins (lower) was discordant in HFpEF versus controls. Data-independent acquisition-mass spectrometry proteomics also yielded 2 HFpEF subgroups; the one most different from controls had a higher proportion of patients with severe obesity and exhibited lower proteins related to fuel metabolism, oxidative phosphorylation, and protein translation. Three modules of correlated proteins in HFpEF that correlated with left ventricular hypertrophy and right ventricular load related to (1) proteasome; (2) fuel metabolism; and (3) protein translation, oxidative phosphorylation, and sarcomere organization.Conclusions Integrative proteomics, transcriptomics, and pathway analysis supports a defect in both metabolism and translation in HFpEF. Patients with HFpEF with more distinct proteomic signatures from control more often had severe obesity, supporting therapeutic efforts targeting metabolism and translation, particularly in this subgroup.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Obesity and Heart Failure with Preserved Ejection Fraction
    Koutroumpakis, Efstratios
    Kaur, Ramanjit
    Taegtmeyer, Heinrich
    Deswal, Anita
    HEART FAILURE CLINICS, 2021, 17 (03) : 345 - 356
  • [42] Management of heart failure with preserved ejection fraction
    Gard, Emma
    Nanayakkara, Shane
    Kaye, David
    Gibbs, Harry
    AUSTRALIAN PRESCRIBER, 2020, 43 (01) : 12 - 17
  • [43] Managing heart failure with preserved ejection fraction
    Davidson, Alexander
    Raviendran, Nivashinie
    Murali, Charisma Nair
    Myint, Phyo Kyaw
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (06)
  • [44] Biomarkers in heart failure with preserved ejection fraction
    W. C. Meijers
    A. R. van der Velde
    R. A. de Boer
    Netherlands Heart Journal, 2016, 24 : 252 - 258
  • [45] Treatment of heart failure with preserved ejection fraction
    Monteverde, Alfredo
    Carlino, Valeria
    Ganci, Giulia
    Taormina, Giuseppe
    Barbagallo, Mario
    MONALDI ARCHIVES FOR CHEST DISEASE, 2018, 88 (02) : 8 - 9
  • [46] Glycolysis in heart failure with preserved ejection fraction
    Lopaschuk, Gary D.
    Sun, Qiuyu
    Ketema, Ezra B.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 (12) : 2576 - 2578
  • [47] Treatment of Heart Failure with Preserved Ejection Fraction
    Iliesiu, Adriana Mihaela
    Hodorogea, Andreea Simona
    HEART FAILURE: FROM RESEARCH TO CLINICAL PRACTICE, VOL 3, 2018, 1067 : 67 - 87
  • [48] Heart Failure With Preserved Ejection Fraction In Perspective
    Pfeffer, Marc A.
    Shah, Amil M.
    Borlaug, Barry A.
    CIRCULATION RESEARCH, 2019, 124 (11) : 1598 - 1617
  • [49] PROGNOSTIC ROLE OF MYOCARDIAL FLOW RESERVE IN HEART FAILURE WITH PRESERVED EJECTION FRACTION
    Kopeva, K., V
    KARDIOLOGIYA, 2023, 63 (12) : 82 - 86
  • [50] Myocardial Injury and Cardiac Reserve in Patients With Heart Failure and Preserved Ejection Fraction
    Obokata, Masaru
    Reddy, Yogesh N. V.
    Melenovsky, Vojtech
    Kane, Garvan C.
    Olson, Thomas P.
    Jarolim, Petr
    Borlaug, Barry A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 72 (01) : 29 - 40